A huge controversy has broken out in the Indian patent and public health space. Apparently, the Indian government offered an alleged under-the-table assurance to USIBC (and other US industry groups) that it will not invoke compulsory licenses (CL’s) anymore, save for public non-commercial use. If true, we have a lot to worry about! Particularly since a CL…

We are pleased to bring you a guest post by Dhruva Gandhi, Sarangan Rajeshkumar and Shubham Jain, all of whom are II year BALLB (Hons.) students at NLS, Bangalore. The authors may be contacted at shubhamjain@nls.ac.in. The Right to Fair Compensation and Transparency in Land Acquisition, Rehabilitation and Resettlement (Amendment) Ordinance, 2014 has been a…

In a piece in the Indian Express a couple of days ago, I expressed some apprehension about the latest round of licensing agreements signed between Gilead and seven Indian generic companies. And argued that since many of our generic majors are now partnering with western multinationals and foregoing the option to challenge their patents, the government must play a…